Brain-derived neurotrophic factor (bdnf) is a neurotrophic gene product that signals primarily through TRKB-related pathways to support neuronal survival, plasticity, and neurite/axonal growth. A key epigenetic feature highlighted here is aberrant methylation at the bdnf locus, which is discussed as a locus-specific alteration in chronic pain-associated neuropsychiatric comorbidities. Therapeutically, bdnf is implicated in osteogenic and neural repair contexts, including hydrogel-driven up-regulation in bone marrow stromal cells (BMSCs) that promotes axonal outgrowth and dorsal root ganglion (DRG) neuron activation. It is also being explored in Friedreich’s ataxia, where activation of this neurotrophic pathway is suggested as a promising way to modulate disease pathophysiology. Recent work includes a 2026 Molecular Neurobiology study showing that the TRKB agonist 7,8-dihydroxyflavone, a partial agonist of bdnf, alleviated DNA damage and apoptosis in a neuronal cell model of Friedreich’s ataxia. Overall, the literature points to bdnf as both an epigenetically altered biomarker and a mechanistic target in pain, neurodegeneration, and regenerative biomaterials.
Chronic pain / neuropsychiatric comorbidity
- Aberrant methylation at the bdnf locus was discussed as part of epigenetic signatures in chronic pain-associated neuropsychiatric co-morbidities. (PMID:41554641)
- The review emphasized locus-specific epigenetic alteration at bdnf, supporting its relevance as a disease-associated regulatory site. (PMID:41554641)
- bdnf was framed as part of broader therapeutic innovation efforts in chronic pain-related neuropsychiatric conditions. (PMID:41554641)
Regenerative medicine / osteointegration
- A multifunctional ion/drug co-delivering nanocomposite hydrogel increased bdnf expression in BMSCs. (PMID:41981450)
- Elevated bdnf was implicated in stimulation of axonal outgrowth, linking the hydrogel to neural repair signaling. (PMID:41981450)
- The same study reported DRG neuron activation, consistent with a neuro-osteogenic microenvironment promoted by bdnf up-regulation. (PMID:41981450)
Neurodegeneration / Friedreich’s ataxia
- Activation of bdnf signaling was suggested as a promising approach for regulating Friedreich’s ataxia pathophysiology. (PMID:42018061)
- In a 2026 Molecular Neurobiology study, the TRKB agonist 7,8-dihydroxyflavone, described as a bdnf partial agonist, alleviated DNA damage and apoptosis in a neuronal cell model of Friedreich’s ataxia. (PMID:42018061)
- These findings support bdnf-linked TRKB activation as a neuroprotective strategy in mitochondrial/neurodegenerative disease contexts. (PMID:42018061)